| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5599369 | Atherosclerosis | 2017 | 7 Pages |
Abstract
While evacetrapib improved traditional atherogenic and putative protective lipid measures compared with ezetimibe and increasing statin dose in patients with ASCVD and/or diabetes, it also adversely affected novel atherogenic risk factors. These findings may contribute to the lack of clinical benefit observed in the ACCELERATE trial.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Stephen J. Nicholls, Kausik K. Ray, Christie M. Ballantyne, Lauren A. Beacham, Debra L. Miller, Giacomo Ruotolo, Steven E. Nissen, Jeffrey S. Riesmeyer, for the ACCENTUATE Investigators for the ACCENTUATE Investigators,